Key result
Extended biventricular assist device support for 12 months in a patient with giant cell myocarditis led to resolution of active disease at the time of heart transplantation.
Case Report (n=1)
Extended biventricular assist device support without immunosuppression may allow for the resolution of active giant cell myocarditis prior to heart transplantation.
Answers are grounded in this paper and cite their sources.
Hypothesis-generating for prolonged BiVAD support in giant cell myocarditis; prospective studies needed before clinical adoption.
Lower recurrence rates and improved long-term outcomes are the goal of treatment for giant cell myocarditis (GCM). We describe a case of GCM in an Asian woman who presented with new onset palpitations and syncope. She initially had normal systolic function by echocardiography with magnetic resonance imaging evidence of infiltrative cardiomyopathy. She underwent implantation of a biventricular assist device (BiVAD) because of rapidly deteriorating hemodynamic status. Giant cell myocarditis was diagnosed at that time by surgical biopsy. She was not treated with immunosuppressive therapy because of low likelihood of recovery and concerns for potential infection with the BiVAD in place. She received a heart transplant 12 months later and had extensive fibrosis but no evidence of active GCM in the heart explant. The role of extended BiVAD support in patients with GCM should be further investigated.
No takes yet. Share an insight, caveat, or question.
Eid et al. (2009) conducted a case report in Giant cell myocarditis (n=1). Biventricular assist device (BiVAD) was evaluated on Resolution of active giant cell myocarditis. Extended biventricular assist device support for 12 months in a patient with giant cell myocarditis led to resolution of active disease at the time of heart transplantation.
Synapse has enriched 10 related papers. Consider them for comparative context: